Monocentric Observational Trial for Florbetaben PET/MRI Hybrid Imaging in Patients With Cardiac Amyloidosis
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:
• Age \> 40 years
• proven Amyloidosis (ATTR or AL)
• Women: negative pregnancy test less than weeks prior imaging.
Locations
Other Locations
Germany
Department of Nuclear medicine, University Hospital Essen
RECRUITING
Essen
Contact Information
Primary
David Kersting, MD, PhD
david.kersting@uk-essen.de
+492017232073
Backup
Lukas Kessler, MD
lukas.kessler@uk-essen.de
+492017232073
Time Frame
Start Date: 2019-12-09
Estimated Completion Date: 2025-12
Participants
Target number of participants: 25
Treatments
Amyloidosis
Oberservation of patients with proven cardiac amyloidosis and Florbetaben PET/MRI as part of diagnostic work up
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Essen